BG
CMD

Bahl & Gaynor’s Cantel Medical Corporation CMD Stock Holding History

Bahl & Gaynor’s Portfolio CMD Stock Details CMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,835
Closed -$256K – 346
2020
Q3 		$256K Hold
5,835
– – ﹤0.01% 311
2020
Q2 		$258K Sell
5,835
-30,034
-84% -$1.12M ﹤0.01% 310
2020
Q1 		$1.29M Sell
35,869
-10,532
-23% -$599K 0.01% 237
2019
Q4 		$3.29M Sell
46,401
-1,472
-3% -$107K 0.02% 190
2019
Q3 		$3.58M Buy
47,873
+11
+0% +$932 0.03% 172
2019
Q2 		$3.86M Sell
47,862
-45,768
-49% -$3.22M 0.03% 164
2019
Q1 		$6.26M Buy
93,630
+3,053
+3% +$231K 0.06% 108
2018
Q4 		$6.74M Buy
90,577
+11,107
+14% +$917K 0.07% 97
2018
Q3 		$7.32M Buy
79,470
+13,008
+20% +$1.24M 0.09% 99
2018
Q2 		$6.54M Buy
66,462
+4,628
+7% +$518K 0.07% 105
2018
Q1 		$6.89M Buy
61,834
+1,850
+3% +$207K 0.08% 103
2017
Q4 		$6.17M Buy
59,984
+1,735
+3% +$173K 0.06% 110
2017
Q3 		$5.49M Buy
58,249
+13,712
+31% +$1.08M 0.06% 112
2017
Q2 		$3.47M Buy
44,537
+3,424
+8% +$257K 0.04% 136
2017
Q1 		$3.29M Buy
41,113
+3,920
+11% +$312K 0.04% 141
2016
Q4 		$2.93M Buy
37,193
+4,800
+15% +$373K 0.04% 143
2016
Q3 		$2.53M Buy
32,393
+2,600
+9% +$189K 0.03% 153
2016
Q2 		$2.05M Buy
29,793
+1,815
+6% +$125K 0.03% 168
2016
Q1 		$2M Buy
27,978
+763
+3% +$47.9K 0.03% 165
2015
Q4 		$1.69M Buy
27,215
+6,522
+32% +$398K 0.02% 177
2015
Q3 		$1.17M Buy
20,693
+2,990
+17% +$158K 0.02% 210
2015
Q2 		$950K Buy
17,703
+790
+5% +$38.4K 0.01% 235
2015
Q1 		$803K Sell
16,913
-3,530
-17% -$156K 0.01% 242
2014
Q4 		$885K Sell
20,443
-5,500
-21% -$225K 0.01% 230
2014
Q3 		$891K Buy
25,943
+3,345
+15% +$118K 0.01% 221
2014
Q2 		$828K Hold
22,598
– – 0.01% 227
2014
Q1 		$762K Buy
22,598
+969
+4% +$32K 0.01% 225
2013
Q4 		$733K Buy
21,629
+1,908
+10% +$66.1K 0.01% 222
2013
Q3 		$628K Sell
19,721
-4
-0% -$106 0.01% 223
2013
Q2 		$445K Buy
+19,725
New +$427K 0.01% 246

Other funds holding CMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return

Bahl & Gaynor's CMD Position: Q4 2020 in Review

Bahl & Gaynor sold out of Cantel Medical Corporation (CMD) in Q4 2020, closing a stake of 5,835 shares — an estimated $256K sold.

Bahl & Gaynor first reported a position in CMD in Q2 2013 and held it in 30 quarters. The position peaked at $7.32M in Q3 2018. 229 funds tracked by Wall St. Rank hold CMD as of Q4 2020.

  • Bahl & Gaynor reported no remaining Cantel Medical Corporation position as of Q4 2020 after selling out during the quarter.
  • Bahl & Gaynor sold 5,835 Cantel Medical Corporation shares in Q4 2020, an estimated $256K.
  • Bahl & Gaynor first reported a position in Cantel Medical Corporation in Q2 2013 and held it in 30 quarters.
  • Bahl & Gaynor's Cantel Medical Corporation position peaked at $7.32M in Q3 2018.
  • 229 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q4 2020.

Based on Bahl & Gaynor's 13F filing for Q4 2020, filed 2 Feb 2021.